Global Monoclonal Antibody for Multiple Myeloma Market Growth (Status and Outlook) 2025-2031

September 2025 | 90 pages | ID: G38325B249CEN
LP Information

Abstracts

According to this study, the global Monoclonal Antibody for Multiple Myeloma market size will reach US$ million by 2031.

United States market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Monoclonal Antibody for Multiple Myeloma players cover Bristol Myers Squibb, Abbvie, Janssen Biotech, Karyopharm Therapeutics, PDL BioPharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Monoclonal Antibody for Multiple Myeloma Industry Forecast” looks at past sales and reviews total world Monoclonal Antibody for Multiple Myeloma sales in 2024, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibody for Multiple Myeloma sales for 2025 through 2031. With Monoclonal Antibody for Multiple Myeloma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibody for Multiple Myeloma industry.

This Insight Report provides a comprehensive analysis of the global Monoclonal Antibody for Multiple Myeloma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Monoclonal Antibody for Multiple Myeloma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Monoclonal Antibody for Multiple Myeloma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibody for Multiple Myeloma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibody for Multiple Myeloma.

This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibody for Multiple Myeloma market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Elotuzumab
• Daratumumab
• Siltuximab
• Dacetuzumab
• Rituximab
• Others

Segmentation by Application:

• Hospital
• Drug Center
• Clinic
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Bristol Myers Squibb
• Abbvie
• Janssen Biotech
• Karyopharm Therapeutics
• PDL BioPharma
• Roche
• Seattle Genetics

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Monoclonal Antibody for Multiple Myeloma Market Size (2020-2031)
  2.1.2 Monoclonal Antibody for Multiple Myeloma Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Monoclonal Antibody for Multiple Myeloma by Country/Region (2020, 2024 & 2031)
2.2 Monoclonal Antibody for Multiple Myeloma Segment by Type
  2.2.1 Elotuzumab
  2.2.2 Daratumumab
  2.2.3 Siltuximab
  2.2.4 Dacetuzumab
  2.2.5 Rituximab
  2.2.6 Others
2.3 Monoclonal Antibody for Multiple Myeloma Market Size by Type
  2.3.1 Monoclonal Antibody for Multiple Myeloma Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Type (2020-2025)
2.4 Monoclonal Antibody for Multiple Myeloma Segment by Application
  2.4.1 Hospital
  2.4.2 Drug Center
  2.4.3 Clinic
  2.4.4 Others
2.5 Monoclonal Antibody for Multiple Myeloma Market Size by Application
  2.5.1 Monoclonal Antibody for Multiple Myeloma Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Application (2020-2025)

3 MONOCLONAL ANTIBODY FOR MULTIPLE MYELOMA MARKET SIZE BY PLAYER

3.1 Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Player
  3.1.1 Global Monoclonal Antibody for Multiple Myeloma Revenue by Player (2020-2025)
  3.1.2 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Player (2020-2025)
3.2 Global Monoclonal Antibody for Multiple Myeloma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 MONOCLONAL ANTIBODY FOR MULTIPLE MYELOMA BY REGION

4.1 Monoclonal Antibody for Multiple Myeloma Market Size by Region (2020-2025)
4.2 Global Monoclonal Antibody for Multiple Myeloma Annual Revenue by Country/Region (2020-2025)
4.3 Americas Monoclonal Antibody for Multiple Myeloma Market Size Growth (2020-2025)
4.4 APAC Monoclonal Antibody for Multiple Myeloma Market Size Growth (2020-2025)
4.5 Europe Monoclonal Antibody for Multiple Myeloma Market Size Growth (2020-2025)
4.6 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Monoclonal Antibody for Multiple Myeloma Market Size by Country (2020-2025)
5.2 Americas Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025)
5.3 Americas Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Monoclonal Antibody for Multiple Myeloma Market Size by Region (2020-2025)
6.2 APAC Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025)
6.3 APAC Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2020-2025)
7.2 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025)
7.3 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Monoclonal Antibody for Multiple Myeloma by Region (2020-2025)
8.2 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025)
8.3 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL MONOCLONAL ANTIBODY FOR MULTIPLE MYELOMA MARKET FORECAST

10.1 Global Monoclonal Antibody for Multiple Myeloma Forecast by Region (2026-2031)
  10.1.1 Global Monoclonal Antibody for Multiple Myeloma Forecast by Region (2026-2031)
  10.1.2 Americas Monoclonal Antibody for Multiple Myeloma Forecast
  10.1.3 APAC Monoclonal Antibody for Multiple Myeloma Forecast
  10.1.4 Europe Monoclonal Antibody for Multiple Myeloma Forecast
  10.1.5 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Forecast
10.2 Americas Monoclonal Antibody for Multiple Myeloma Forecast by Country (2026-2031)
  10.2.1 United States Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.2.2 Canada Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.2.3 Mexico Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.2.4 Brazil Market Monoclonal Antibody for Multiple Myeloma Forecast
10.3 APAC Monoclonal Antibody for Multiple Myeloma Forecast by Region (2026-2031)
  10.3.1 China Monoclonal Antibody for Multiple Myeloma Market Forecast
  10.3.2 Japan Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.3.3 Korea Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.3.4 Southeast Asia Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.3.5 India Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.3.6 Australia Market Monoclonal Antibody for Multiple Myeloma Forecast
10.4 Europe Monoclonal Antibody for Multiple Myeloma Forecast by Country (2026-2031)
  10.4.1 Germany Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.4.2 France Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.4.3 UK Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.4.4 Italy Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.4.5 Russia Market Monoclonal Antibody for Multiple Myeloma Forecast
10.5 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Forecast by Region (2026-2031)
  10.5.1 Egypt Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.5.2 South Africa Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.5.3 Israel Market Monoclonal Antibody for Multiple Myeloma Forecast
  10.5.4 Turkey Market Monoclonal Antibody for Multiple Myeloma Forecast
10.6 Global Monoclonal Antibody for Multiple Myeloma Forecast by Type (2026-2031)
10.7 Global Monoclonal Antibody for Multiple Myeloma Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Monoclonal Antibody for Multiple Myeloma Forecast

11 KEY PLAYERS ANALYSIS

11.1 Bristol Myers Squibb
  11.1.1 Bristol Myers Squibb Company Information
  11.1.2 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Product Offered
  11.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Bristol Myers Squibb Main Business Overview
  11.1.5 Bristol Myers Squibb Latest Developments
11.2 Abbvie
  11.2.1 Abbvie Company Information
  11.2.2 Abbvie Monoclonal Antibody for Multiple Myeloma Product Offered
  11.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Abbvie Main Business Overview
  11.2.5 Abbvie Latest Developments
11.3 Janssen Biotech
  11.3.1 Janssen Biotech Company Information
  11.3.2 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Product Offered
  11.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Janssen Biotech Main Business Overview
  11.3.5 Janssen Biotech Latest Developments
11.4 Karyopharm Therapeutics
  11.4.1 Karyopharm Therapeutics Company Information
  11.4.2 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Product Offered
  11.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Karyopharm Therapeutics Main Business Overview
  11.4.5 Karyopharm Therapeutics Latest Developments
11.5 PDL BioPharma
  11.5.1 PDL BioPharma Company Information
  11.5.2 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Product Offered
  11.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 PDL BioPharma Main Business Overview
  11.5.5 PDL BioPharma Latest Developments
11.6 Roche
  11.6.1 Roche Company Information
  11.6.2 Roche Monoclonal Antibody for Multiple Myeloma Product Offered
  11.6.3 Roche Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Roche Main Business Overview
  11.6.5 Roche Latest Developments
11.7 Seattle Genetics
  11.7.1 Seattle Genetics Company Information
  11.7.2 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Product Offered
  11.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Seattle Genetics Main Business Overview
  11.7.5 Seattle Genetics Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Monoclonal Antibody for Multiple Myeloma Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Monoclonal Antibody for Multiple Myeloma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Elotuzumab
Table 4. Major Players of Daratumumab
Table 5. Major Players of Siltuximab
Table 6. Major Players of Dacetuzumab
Table 7. Major Players of Rituximab
Table 8. Major Players of Others
Table 9. Monoclonal Antibody for Multiple Myeloma Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 11. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Table 12. Monoclonal Antibody for Multiple Myeloma Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 13. Global Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 14. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Table 15. Global Monoclonal Antibody for Multiple Myeloma Revenue by Player (2020-2025) & ($ millions)
Table 16. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Player (2020-2025)
Table 17. Monoclonal Antibody for Multiple Myeloma Key Players Head office and Products Offered
Table 18. Monoclonal Antibody for Multiple Myeloma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Monoclonal Antibody for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 22. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Table 23. Global Monoclonal Antibody for Multiple Myeloma Revenue by Country/Region (2020-2025) & ($ millions)
Table 24. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Country/Region (2020-2025)
Table 25. Americas Monoclonal Antibody for Multiple Myeloma Market Size by Country (2020-2025) & ($ millions)
Table 26. Americas Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Country (2020-2025)
Table 27. Americas Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 28. Americas Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Table 29. Americas Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 30. Americas Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Table 31. APAC Monoclonal Antibody for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 32. APAC Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Table 33. APAC Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 34. APAC Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 35. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2020-2025) & ($ millions)
Table 36. Europe Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Country (2020-2025)
Table 37. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 38. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 39. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 40. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 41. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Monoclonal Antibody for Multiple Myeloma
Table 43. Key Market Challenges & Risks of Monoclonal Antibody for Multiple Myeloma
Table 44. Key Industry Trends of Monoclonal Antibody for Multiple Myeloma
Table 45. Global Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Region (2026-2031) & ($ millions)
Table 46. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share Forecast by Region (2026-2031)
Table 47. Global Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Type (2026-2031) & ($ millions)
Table 48. Global Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Application (2026-2031) & ($ millions)
Table 49. Bristol Myers Squibb Details, Company Type, Monoclonal Antibody for Multiple Myeloma Area Served and Its Competitors
Table 50. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Product Offered
Table 51. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 52. Bristol Myers Squibb Main Business
Table 53. Bristol Myers Squibb Latest Developments
Table 54. Abbvie Details, Company Type, Monoclonal Antibody for Multiple Myeloma Area Served and Its Competitors
Table 55. Abbvie Monoclonal Antibody for Multiple Myeloma Product Offered
Table 56. Abbvie Monoclonal Antibody for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 57. Abbvie Main Business
Table 58. Abbvie Latest Developments
Table 59. Janssen Biotech Details, Company Type, Monoclonal Antibody for Multiple Myeloma Area Served and Its Competitors
Table 60. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Product Offered
Table 61. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 62. Janssen Biotech Main Business
Table 63. Janssen Biotech Latest Developments
Table 64. Karyopharm Therapeutics Details, Company Type, Monoclonal Antibody for Multiple Myeloma Area Served and Its Competitors
Table 65. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Product Offered
Table 66. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 67. Karyopharm Therapeutics Main Business
Table 68. Karyopharm Therapeutics Latest Developments
Table 69. PDL BioPharma Details, Company Type, Monoclonal Antibody for Multiple Myeloma Area Served and Its Competitors
Table 70. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Product Offered
Table 71. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 72. PDL BioPharma Main Business
Table 73. PDL BioPharma Latest Developments
Table 74. Roche Details, Company Type, Monoclonal Antibody for Multiple Myeloma Area Served and Its Competitors
Table 75. Roche Monoclonal Antibody for Multiple Myeloma Product Offered
Table 76. Roche Monoclonal Antibody for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 77. Roche Main Business
Table 78. Roche Latest Developments
Table 79. Seattle Genetics Details, Company Type, Monoclonal Antibody for Multiple Myeloma Area Served and Its Competitors
Table 80. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Product Offered
Table 81. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 82. Seattle Genetics Main Business
Table 83. Seattle Genetics Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Monoclonal Antibody for Multiple Myeloma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Monoclonal Antibody for Multiple Myeloma Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Monoclonal Antibody for Multiple Myeloma Sales Market Share by Country/Region (2024)
Figure 8. Monoclonal Antibody for Multiple Myeloma Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Type in 2024
Figure 10. Monoclonal Antibody for Multiple Myeloma in Hospital
Figure 11. Global Monoclonal Antibody for Multiple Myeloma Market: Hospital (2020-2025) & ($ millions)
Figure 12. Monoclonal Antibody for Multiple Myeloma in Drug Center
Figure 13. Global Monoclonal Antibody for Multiple Myeloma Market: Drug Center (2020-2025) & ($ millions)
Figure 14. Monoclonal Antibody for Multiple Myeloma in Clinic
Figure 15. Global Monoclonal Antibody for Multiple Myeloma Market: Clinic (2020-2025) & ($ millions)
Figure 16. Monoclonal Antibody for Multiple Myeloma in Others
Figure 17. Global Monoclonal Antibody for Multiple Myeloma Market: Others (2020-2025) & ($ millions)
Figure 18. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Application in 2024
Figure 19. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Player in 2024
Figure 20. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Figure 21. Americas Monoclonal Antibody for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 22. APAC Monoclonal Antibody for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 23. Europe Monoclonal Antibody for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 24. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 25. Americas Monoclonal Antibody for Multiple Myeloma Value Market Share by Country in 2024
Figure 26. United States Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 27. Canada Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 28. Mexico Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 29. Brazil Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 30. APAC Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Region in 2024
Figure 31. APAC Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 32. APAC Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 33. China Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 34. Japan Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 35. South Korea Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 36. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 37. India Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 38. Australia Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 39. Europe Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Country in 2024
Figure 40. Europe Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 41. Europe Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 42. Germany Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 43. France Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 44. UK Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 45. Italy Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 46. Russia Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 47. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Figure 48. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 49. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 50. Egypt Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 51. South Africa Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 52. Israel Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 53. Turkey Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 54. GCC Countries Monoclonal Antibody for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 55. Americas Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 56. APAC Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 57. Europe Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 58. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 59. United States Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 60. Canada Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 61. Mexico Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 62. Brazil Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 63. China Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 64. Japan Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 65. Korea Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 66. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 67. India Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 68. Australia Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 69. Germany Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 70. France Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 71. UK Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 72. Italy Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 73. Russia Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 74. Egypt Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 75. South Africa Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 76. Israel Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 77. Turkey Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 78. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share Forecast by Type (2026-2031)
Figure 79. Global Monoclonal Antibody for Multiple Myeloma Market Size Market Share Forecast by Application (2026-2031)
Figure 80. GCC Countries Monoclonal Antibody for Multiple Myeloma Market Size 2026-2031 ($ millions)